Browse News
Filter News
Found 13 articles
-
New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the European Society of Hypertension Annual Meeting 2023
6/26/2023
Idorsia Ltd (SIX: IDIA) today announced that further data for aprocitentan, Idorsia’s investigational dual endothelin receptor antagonist evaluating the treatment of patients with resistant hypertension, were presented as an oral presentation.
-
Fresh off of his Sanofi exit, John Reed is joining Johnson & Johnson, where he will serve as executive vice president, pharmaceuticals, R&D.
-
Johnson & Johnson Reports Q4 and Full-Year 2022 Results
1/24/2023
Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2022.
-
Idorsia submits a New Drug Application to the US FDA for aprocitentan for the treatment of patients with difficult-to-control hypertension
12/20/2022
Idorsia Ltd announced that it has submitted a New Drug Application to the US Food and Drug Administration seeking approval for aprocitentan, Idorsia’s investigational, novel dual endothelin receptor antagonist, for the treatment of patients with difficult-to-control hypertension.
-
Late-Breaking Data from Pivotal Phase 3 PRECISION Study Demonstrates Significant and Sustained Effect of Aprocitentan on Lowering Blood Pressure for Patients with Difficult-to-Control Hypertension
11/7/2022
The Janssen Pharmaceutical Companies of Johnson & Johnson, in collaboration with Idorsia Ltd, today announced results from the Phase 3 PRECISION study.
-
Idorsia announces financial results for the first half 2022 – reaching commercial stage
7/26/2022
Idorsia Ltd announced its financial results for the first half of 2022.
-
Several biopharma companies are opening the week with positive clinical trial news. Read on for updates from Cytokinetics, Concert Pharmaceuticals, Idorsia and Seagen.
-
Idorsia announces financial results for 2021 – 2022 to be a transformative year – Sustainable profitability expected in 2025
2/8/2022
QUVIVIQ™ (daridorexant) 25 mg and 50 mg approved by the US Food and Drug Administration (FDA) for the treatment of adults with insomnia.
-
Idorsia announces financial results for the first half 2021 – Building momentum towards becoming a fully-fledged biopharmaceutical company
7/27/2021
The company is making great progress with delivering on the strategic priorities we defined on Day 1 of Idorsia.
-
Idorsia Announces Financial Results For 2017 - Company Off to a Great Start - 4 Compounds to Enter Phase III Development
2/6/2018
The company announced its financial results as of December 31, 2017, which represent the business activities for the six and a half months since the demerger from Actelion on June 15, 2017.
-
Today, Janssen Biotech announced it had exercised its option to enter into a collaboration deal with Idorsia to jointly develop and market aprocitentan and any derivative compounds.
-
Idorsia - Reaching Out For More
6/19/2017
-
Publication Of Idorsia's Prospectus Relating To The Listing Of Idorsia Ltd On Six Swiss Exchange
6/9/2017